Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 25%High 1 · 25%

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham

QoL · adults with GA due to AMD

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1003 participants
Moderate

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

QoL · adults with GA due to AMD

The review found no eligible studies for this question.

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham

QoL · adults with GA due to AMD

The review found no eligible studies for this question.

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham

QoL · adults with GA due to AMD

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 983 participants
High